Tags

Type your tag names separated by a space and hit enter

Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Int J Rheum Dis. 2018 Oct; 21(10):1815-1821.IJ

Abstract

AIM

This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA.

METHODS

We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA patients with CRP > 1.0 mg/dL (n = 10) and healthy subjects (n = 10) and examined the fraction of oxidized albumin (oxidized-albumin [%]) as a marker of oxidative stress in addition to inflammatory measures and disease activity scores such as CRP, erythrocyte sedimentation rate (ESR), matrix metalloproteinase 3 (MMP-3), serum amyloid A (SAA), Clinical Disease Activity Index, Simplified Disease Activity Index, visual analog scale (VAS), Disease Activity Index of 28 joints (DAS28)-CRP, DAS28-ESR and renal function (creatinine clearance [CCr]).

RESULTS

Oxidized-albumin (%) was significantly elevated among active RA patients (33.83 ± 5.31%) as compared with healthy subjects (23.00 ± 2.56%). Although oxidized-albumin (%) among well-controlled RA patients also increased, there was no difference with oxidized-albumin (%) between infliximab and tocilizumab groups (26.40 ± 5.44% in infliximab; 26.62 ± 4.53% in tocilizumab). In Pearson's correlation, oxidized-albumin (%) had significant correlations with CRP, MMP-3, ESR, SAA, age, CCr, VAS, DAS28-CRP and DAS28-ESR. With those variables, multiple stepwise forward regression analysis was conducted and revealed that CCr, DAS28-ESR and CRP are the statistically significant explanatory variables on oxidized-albumin (%) among well-controlled RA patients.

CONCLUSIONS

We demonstrated that there was no difference with infliximab and tocilizumab on oxidative stress and we clarified that CCr, DAS28-ESR and CRP become indicative factors of oxidative stress among well-controlled RA patients.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kizaki K
Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, Kyoto, Japan.
Yamashita F
Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, Kyoto, Japan.
Hayashi T
Department of Sports Science, Meiji University of Integrative Medicine, Kyoto, Japan.
Funakoshi N
Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, Kyoto, Japan.

MeSH

AgedAntibodies, Monoclonal, HumanizedAntioxidantsAntirheumatic AgentsArthritis, RheumatoidBiomarkersBlood SedimentationC-Reactive ProteinCase-Control StudiesFemaleHumansInflammation MediatorsInfliximabMaleMatrix Metalloproteinase 3Middle AgedOxidation-ReductionOxidative StressSerum Albumin, HumanSerum Amyloid A ProteinTime FactorsTreatment Outcome

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

27778459

Citation

Kizaki, Kazuha, et al. "Infliximab Equivalently Suppresses Oxidative Stress Compared to Tocilizumab Among Well-controlled Patients With Rheumatoid Arthritis." International Journal of Rheumatic Diseases, vol. 21, no. 10, 2018, pp. 1815-1821.
Kizaki K, Yamashita F, Hayashi T, et al. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. Int J Rheum Dis. 2018;21(10):1815-1821.
Kizaki, K., Yamashita, F., Hayashi, T., & Funakoshi, N. (2018). Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 21(10), 1815-1821. https://doi.org/10.1111/1756-185X.12972
Kizaki K, et al. Infliximab Equivalently Suppresses Oxidative Stress Compared to Tocilizumab Among Well-controlled Patients With Rheumatoid Arthritis. Int J Rheum Dis. 2018;21(10):1815-1821. PubMed PMID: 27778459.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. AU - Kizaki,Kazuha, AU - Yamashita,Fumiharu, AU - Hayashi,Tomoya, AU - Funakoshi,Noboru, Y1 - 2016/10/24/ PY - 2016/10/26/pubmed PY - 2019/4/10/medline PY - 2016/10/26/entrez KW - albumin KW - infliximab KW - rheumatoid arthritis KW - tocilizumab SP - 1815 EP - 1821 JF - International journal of rheumatic diseases JO - Int J Rheum Dis VL - 21 IS - 10 N2 - AIM: This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA. METHODS: We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA patients with CRP > 1.0 mg/dL (n = 10) and healthy subjects (n = 10) and examined the fraction of oxidized albumin (oxidized-albumin [%]) as a marker of oxidative stress in addition to inflammatory measures and disease activity scores such as CRP, erythrocyte sedimentation rate (ESR), matrix metalloproteinase 3 (MMP-3), serum amyloid A (SAA), Clinical Disease Activity Index, Simplified Disease Activity Index, visual analog scale (VAS), Disease Activity Index of 28 joints (DAS28)-CRP, DAS28-ESR and renal function (creatinine clearance [CCr]). RESULTS: Oxidized-albumin (%) was significantly elevated among active RA patients (33.83 ± 5.31%) as compared with healthy subjects (23.00 ± 2.56%). Although oxidized-albumin (%) among well-controlled RA patients also increased, there was no difference with oxidized-albumin (%) between infliximab and tocilizumab groups (26.40 ± 5.44% in infliximab; 26.62 ± 4.53% in tocilizumab). In Pearson's correlation, oxidized-albumin (%) had significant correlations with CRP, MMP-3, ESR, SAA, age, CCr, VAS, DAS28-CRP and DAS28-ESR. With those variables, multiple stepwise forward regression analysis was conducted and revealed that CCr, DAS28-ESR and CRP are the statistically significant explanatory variables on oxidized-albumin (%) among well-controlled RA patients. CONCLUSIONS: We demonstrated that there was no difference with infliximab and tocilizumab on oxidative stress and we clarified that CCr, DAS28-ESR and CRP become indicative factors of oxidative stress among well-controlled RA patients. SN - 1756-185X UR - https://www.unboundmedicine.com/medline/citation/27778459/Infliximab_equivalently_suppresses_oxidative_stress_compared_to_tocilizumab_among_well_controlled_patients_with_rheumatoid_arthritis_ DB - PRIME DP - Unbound Medicine ER -